SCHEMBL234529

SCHEMBL234529

Oc1ccc(-c2ccc3ccccc3c2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 10/20 1.00
ESR2 Q92731 10/20 1.00
HSD17B1 P14061 4/20 0.69
HSD17B2 P37059 4/20 0.69
ALOX5 P09917 1/20 0.65
CYP1A2 P05177 2/20 0.65
CYP3A4 P08684 1/20 0.59
CYP2D6 P10635 1/20 0.59
CYP2C9 P11712 1/20 0.59
CYP2B6 P20813 1/20 0.59
CYP2C19 P33261 1/20 0.59
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
MMP3 P08254 1/20 0.56
BCL2L1 Q07817 1/20 0.56
ABL1 P00519 1/20 0.56
ABCB1 P08183 1/20 0.56
BCR P11274 1/20 0.56
NPC1 O15118 1/20 0.55
HSP90AA1 P07900 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29672355 1.00 ESR1 (1.00) ESR1ESR2HSD17B1HSD17B2ALOX5
SCHEMBL27616561 0.93 ESR1 (0.87) ESR1ESR2HSD17B1HSD17B2ALOX5
SCHEMBL3107306 0.91 ESR2 (0.83) ESR1ESR2HSD17B1HSD17B2ALOX5
SCHEMBL14506125 0.91 ESR2 (0.83) ESR1ESR2HSD17B1HSD17B2ALOX5
SCHEMBL11978649 0.88 ESR2 (0.80) ESR1ESR2HSD17B1HSD17B2ALOX5
SCHEMBL29587268 0.88 ESR2 (0.80) ESR1ESR2HSD17B1HSD17B2ALOX5
SCHEMBL31039575 0.87 ESR1 (0.76) ESR1ESR2HSD17B1HSD17B2ALOX5
Naphthalene SCHEMBL11342178 0.87 ESR1 (0.76) ESR1ESR2HSD17B1HSD17B2CYP1A2
SCHEMBL18260181 0.87 ESR1 (0.76) ESR1ESR2HSD17B1HSD17B2ALOX5
SCHEMBL27433243 0.86 ESR1 (0.76) ESR1ESR2HSD17B1HSD17B2ALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 388 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12187911-B2 Method for preparing water-soluble acrylic-modified phenolic-modified epoxy resin, water-soluble acrylic-modified phenolic-modified epoxy resin prepared thereby, and aqueous coating composition comprising same SAMHWA PAINTS INDUSTRIES CO., LTD. (KR) 2025-01-07 US claimed
US-20240117213-A1 METHOD FOR PREPARING WATER-SOLUBLE ACRYLIC-MODIFIED PHENOLIC-MODIFIED EPOXY RESIN, WATER-SOLUBLE ACRYLIC-MODIFIED PHENOLIC-MODIFIED EPOXY RESIN PREPARED THEREBY, AND AQUEOUS COATING COMPOSITION COMPRISING SAME SAMHWA PAINTS INDUSTRIES CO., LTD. (KR) 2024-04-11 US claimed
CN-117776963-A Synthesis method of phenol by diazotization 新疆大学 2024-03-29 CN claimed
WO-2021075800-A1 METHOD FOR PREPARING WATER-SOLUBLE ACRYLIC-MODIFIED PHENOLIC-MODIFIED EPOXY RESIN, WATER-SOLUBLE ACRYLIC-MODIFIED PHENOLIC-MODIFIED EPOXY RESIN PREPARED THEREBY, AND AQUEOUS COATING COMPOSITION COMPRISING SAME 삼화페인트공업주식회사 2021-04-22 WO claimed
CN-106831361-B A kind of method that dihalo trifluoroethane prepares trifluoro vinyl virtue ether compound 中昊晨光化工研究院有限公司 2019-06-25 CN claimed
CN-106632239-B A kind of isolonglifolane ketone group hexahydro quinazoline -2- amine schiff's base type fluorescent material and its synthetic method and application 南京林业大学 2019-04-12 CN claimed
CN-108779248-A Benzylated Mannich base curatives, compositions, and methods 赢创德固赛有限公司 2018-11-09 CN claimed
CN-108697709-A Methods for treating huntington's disease PTC医疗公司 2018-10-23 CN claimed
CN-108277514-A A kind of preparation method of plating dehydrating agent 常州五荣化工有限公司 2018-07-13 CN claimed
CN-108255014-A A kind of dry film photoresist containing modified polyurethane and photo-curing monomer 珠海市能动科技光学产业有限公司 2018-07-06 CN claimed
CN-106831361-A A kind of method that dihalo HFC-143a prepares trifluoro vinyl virtue ether compound 中昊晨光化工研究院有限公司 2017-06-13 CN claimed
US-8242130-B2 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2012-08-14 US claimed
US-8093273-B2 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2012-01-10 US claimed
EP-2332527-A2 Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2011-06-15 EP claimed
EP-1838296-A2 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. (CA) 2007-10-03 EP claimed
US-20060205767-A1 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases HEPALINK (HONG KONG) LIMITED (HK) 2006-09-14 US claimed
WO-2006045096-A2 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. (CA) 2006-04-27 WO claimed
US-12600116-B2 Special polymer layers for faster laminability of multilayer structures COVESTRO DEUTSCHLAND AG (DE) 2026-04-14 US disclosed
US-3959353-A Esters of hydroxyaryl adducts of decachloropentacyclo (5.3.0.02,6.04,10 05,9) decane-3-one HOOKER CHEMICALS & PLASTICS CORPORATION (US) 1976-05-25 US disclosed
US-3945959-A ELECTRICAL INSULATION, CONDUCTORS THE P. D. GEORGE CO. (US) 1976-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205767-A1 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases APOB, APOL1, FABP3 ESR1 357/4885ESR2 290/4885HSD17B1 448/4885
US-12600116-B2 Special polymer layers for faster laminability of multilayer structures ASH2L, SMC2, ELL ESR1 1394/4885ESR2 2120/4885HSD17B1 4596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.